title: Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure.
abstract: BACKGROUND
  The aim of this study was to assess the effects of albumin dialysis on hepatic encephalopathy and circulating levels of amino acids in severe alcoholic hepatitis.
  
  
  METHODS
  The study was carried out in nine patients with severe alcoholic hepatitis and four with primary biliary cirrhosis treated with the molecular adsorbent recirculating system. Besides standard liver function tests, circulating levels of ammonia, total, branched chain and aromatic amino acids, the presence and severity of hepatic encephalopathy, and number connection test were measured before and after each treatment.
  
  
  RESULTS
  There were eight episodes of encephalopathy in patients with alcoholic hepatitis. Albumin dialysis was associated with significant improvement in encephalopathy (p = 0.02), and a decrease in total amino acid levels (2490 +/- 152 microM to 2229 +/- 114 microM, p < 0.001). Moreover, the Fischer's ratio, which was significantly lower in patients with alcoholic hepatitis (1.32 +/- 0.08) than in controls (3.20 +/- 0.16), increased by 17% after albumin dialysis (p < 0.02) because of a significant decrease in phenolic aromatic amino acids (193 +/- 17 microM to 165 +/- 9 microM, p = 0.04). No differences were observed in circulating ammonia. Changes in phenolic aromatic amino acids and the Fischer's ratio were more prominent in patients with encephalopathy and higher bilirubin removal. Albumin dialysis did not significantly affect the amino acid profile in the controls.
  
  
  CONCLUSIONS
  Albumin dialysis results in a significant decrease in circulating phenolic aromatic amino acids and improvement of hepatic encephalopathy in patients with severe liver failure.
authors.affiliation: Liver Unit, Digestive Diseases Institute, Hospital Clínic, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. pares@ub.edu
authors.forename: Albert
authors.initials: A
authors.lastname: Parés
authors.forename: Ramón
authors.initials: R
authors.lastname: Deulofeu
authors.forename: Laura
authors.initials: L
authors.lastname: Cisneros
authors.forename: Angels
authors.initials: A
authors.lastname: Escorsell
authors.forename: Joan Manuel
authors.initials: JM
authors.lastname: Salmerón
authors.forename: Joan
authors.initials: J
authors.lastname: Caballería
authors.forename: Antoni
authors.initials: A
authors.lastname: Mas
mesh_terms: D000418:Albumins / Q000008:administration & dosage*; D024322:Amino Acids, Aromatic / Q000378:metabolism*; D003956:Dialysis / Q000379:methods*; D005260:Female; D006501:Hepatic Encephalopathy / Q000097:blood / Q000150:complications / Q000628:therapy*; D006519:Hepatitis, Alcoholic / Q000097:blood / Q000150:complications / Q000628:therapy*; D006801:Humans; D017093:Liver Failure / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000097:blood
chemical_list: D000418:Albumins; D024322:Amino Acids, Aromatic; D010636:Phenols